JP6429191B2 - アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用 - Google Patents

アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用 Download PDF

Info

Publication number
JP6429191B2
JP6429191B2 JP2014560516A JP2014560516A JP6429191B2 JP 6429191 B2 JP6429191 B2 JP 6429191B2 JP 2014560516 A JP2014560516 A JP 2014560516A JP 2014560516 A JP2014560516 A JP 2014560516A JP 6429191 B2 JP6429191 B2 JP 6429191B2
Authority
JP
Japan
Prior art keywords
cells
cell
apoptosis
fasl
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014560516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510758A (ja
JP2015510758A5 (cg-RX-API-DMAC7.html
Inventor
ヤーコニ，シャイ
アシュケナージ，ナディール
Original Assignee
セレクト バイオセラピューティクス リミテッド
セレクト バイオセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレクト バイオセラピューティクス リミテッド, セレクト バイオセラピューティクス リミテッド filed Critical セレクト バイオセラピューティクス リミテッド
Publication of JP2015510758A publication Critical patent/JP2015510758A/ja
Publication of JP2015510758A5 publication Critical patent/JP2015510758A5/ja
Application granted granted Critical
Publication of JP6429191B2 publication Critical patent/JP6429191B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
JP2014560516A 2012-03-06 2013-03-05 アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用 Expired - Fee Related JP6429191B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607033P 2012-03-06 2012-03-06
PCT/IL2013/000026 WO2013132477A1 (en) 2012-03-06 2013-03-05 Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof

Publications (3)

Publication Number Publication Date
JP2015510758A JP2015510758A (ja) 2015-04-13
JP2015510758A5 JP2015510758A5 (cg-RX-API-DMAC7.html) 2016-04-21
JP6429191B2 true JP6429191B2 (ja) 2018-11-28

Family

ID=49116028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560516A Expired - Fee Related JP6429191B2 (ja) 2012-03-06 2013-03-05 アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用

Country Status (11)

Country Link
US (2) US9783778B2 (cg-RX-API-DMAC7.html)
EP (2) EP3486315A1 (cg-RX-API-DMAC7.html)
JP (1) JP6429191B2 (cg-RX-API-DMAC7.html)
KR (1) KR101912982B1 (cg-RX-API-DMAC7.html)
CN (2) CN104245924B (cg-RX-API-DMAC7.html)
AU (1) AU2013229008B2 (cg-RX-API-DMAC7.html)
CA (1) CA2866358C (cg-RX-API-DMAC7.html)
DK (1) DK2823040T3 (cg-RX-API-DMAC7.html)
IL (1) IL234459B (cg-RX-API-DMAC7.html)
RU (1) RU2630301C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013132477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538253A (ja) * 2013-10-09 2016-12-08 セレクト バイオセラピューティクス リミテッド デスリガンドへの移植前曝露による造血前駆細胞の活性化
EP3303563B1 (en) 2015-06-05 2020-05-27 Cellect Biotherapeutics Ltd. Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof
WO2020039446A1 (en) * 2018-08-22 2020-02-27 Cellect Biotherapeutics Ltd. Modulation of apoptosis susceptible cells
US20220002363A1 (en) * 2020-07-03 2022-01-06 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating pulmonary disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
JPS61235752A (ja) 1985-04-11 1986-10-21 Asahi Optical Co Ltd 細胞分離材、分離器および分離方法
IT8523298V0 (it) * 1985-10-02 1985-10-02 Pierrel Hospital Spa Catetere venoso centrale.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4979959A (en) 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
US4885234A (en) 1988-09-29 1989-12-05 Eastman Kodak Company Photographic materials containing stable cyan coupler formulations
US5998024A (en) 1995-02-02 1999-12-07 Rainer H. Frey Biocompatible material and method of manufacture and use thereof
HUP0003349A3 (en) 1997-05-14 2001-12-28 Aventis Pharmaceuticals Inc Co Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use
US6040182A (en) 1997-11-12 2000-03-21 Becton Dickinson And Company Method and materials for efficiency protein immobilization on tissue culture treated assay plates
GB9724270D0 (en) 1997-11-17 1998-01-14 Babraham The Inst Methods and means for mutagenesis of dna
WO1999054266A1 (en) 1998-04-22 1999-10-28 St. Jude Medical Ab Biocompatible material for implants
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
US20090130718A1 (en) 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
WO2003002761A1 (en) 2001-06-29 2003-01-09 Novozymes A/S Method of multimerization and site-directed mutagenesis
AU2002365177A1 (en) 2001-07-02 2003-07-24 The Board Of Trustees Of The Leland Stanford Junior University Microarrays for cell phenotyping and manipulation
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
ATE438857T1 (de) * 2002-06-13 2009-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihren verwendung für krebs therapie und transplantation
EP1551449B1 (en) * 2002-07-12 2010-10-06 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
US20060009623A1 (en) 2004-07-06 2006-01-12 National University Of Singapore C-terminal attachment of ligands to proteins for immobilization onto a support
ATE482268T1 (de) * 2004-10-01 2010-10-15 Topotarget Switzerland Sa Ex-vivo-spülverfahren für autologe transplantationen mittels löslicher fasl-moleküle
EP1812555B1 (en) * 2004-10-25 2015-04-22 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
EP1800613B1 (en) * 2005-12-23 2008-07-16 BIEDERMANN MOTECH GmbH Flexible stabilization device for dynamic stabilization of bones or vertebrae
CN101517070A (zh) * 2006-05-31 2009-08-26 Styx有限责任公司 选择干细胞的方法及其用途
CA2653881C (en) 2006-05-31 2016-08-23 Styx Llc Methods of selecting stem cells and uses thereof
ES2558543T3 (es) * 2007-03-16 2016-02-05 Cellestis Limited Un ensayo de respuesta inmunitaria mediada por células y kits para el mismo
KR100920729B1 (ko) 2007-10-01 2009-10-07 한국생명공학연구원 펩타이드 혼성체를 사용한 배향성이 조절된 항체단분자막의 제조방법
WO2009154840A2 (en) 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
CN102123746B (zh) * 2008-06-13 2016-01-06 史密夫和内修有限公司 用于组织修复的固定装置
CA2741426C (en) * 2008-10-31 2020-04-21 Meredith Hans Method and device for activating stem cells
GB0823553D0 (en) 2008-12-24 2009-01-28 Immunosolv Ltd Cell separation technique
JP2010227313A (ja) 2009-03-27 2010-10-14 Seiko Epson Corp がん細胞除去システムおよびがん細胞除去装置
JP5327457B2 (ja) 2009-03-27 2013-10-30 セイコーエプソン株式会社 がん細胞分離装置およびその製造方法
CA2804914A1 (en) * 2010-07-22 2012-01-26 Nadir Askenasy Regulatory immune cells with enhanced targeted cell death effect

Also Published As

Publication number Publication date
CN109116033A (zh) 2019-01-01
EP3486315A1 (en) 2019-05-22
IL234459B (en) 2020-02-27
US20150044182A1 (en) 2015-02-12
US20180208888A1 (en) 2018-07-26
EP2823040A1 (en) 2015-01-14
EP2823040A4 (en) 2016-01-06
RU2630301C2 (ru) 2017-09-06
CA2866358A1 (en) 2013-09-12
KR20150011796A (ko) 2015-02-02
DK2823040T3 (en) 2018-11-19
CN104245924B (zh) 2020-05-01
US9783778B2 (en) 2017-10-10
AU2013229008B2 (en) 2018-11-08
CA2866358C (en) 2020-06-23
CN104245924A (zh) 2014-12-24
JP2015510758A (ja) 2015-04-13
EP2823040B1 (en) 2018-08-01
RU2014138001A (ru) 2016-04-20
WO2013132477A1 (en) 2013-09-12
KR101912982B1 (ko) 2018-10-29
AU2013229008A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
Socié et al. Acute graft-versus-host disease: from the bench to the bedside
Mallet et al. Bone marrow transplantation in mice leads to a minor population of hepatocytes that can be selectively amplified in vivo
KR102489954B1 (ko) 인간 백혈구 항원 제한된 감마 델타 t 세포 수용체 및 이의 사용 방법
EP2126051B1 (en) A method for expanding monocytes
Boieri et al. The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: a historical overview
Morris et al. Advances in the understanding of acute graft‐versus‐host disease
JP5977238B2 (ja) 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用
JP6429191B2 (ja) アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用
Gail et al. Complex interactions of cellular players in chronic Graft-versus-Host Disease
KR20050047500A (ko) 중간엽기질세포를 이용한 생착증진 방법
JP2025063190A (ja) リンホトキシンアルファ遮断剤によりターゲットされた制御性ｔ細胞及びその使用
KR20060040671A (ko) 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도
WO2013076245A1 (en) Allogeneic immune response control
Muraro et al. Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS
Sprangers et al. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease
KR20230019117A (ko) 개선된 백신 제제
EP1223963A2 (en) T-cells and molecules involved in immune regulation
Takenouchi et al. THE MECHANISM OF IMMUNOSUPPRESSIVE EFFECT IN VIVO OF NOVEL IMMUNOSUPPRESSIVE DRUG, Β-SQAG9 THAT INHIBITS THE RESPONSE OF CD62L+ T CELL SUBSET
Or-Geva induction of immune tolerance by veto cells
Jones The immunobiology of graft-versus-host disease across a minor histocompatibility antigen barrier
Sala Mesenchymal stem cells: mechanisms involved in the treatment of Inflammatory Bowel Disease
Hoerbelt et al. PRE-TRANSPLANT DONOR-SPECIFC TRANSFUSIONS COMBINED WITH CYCLOSPORINE BUT NOT WITH RAPAMYCIN INDUCE TOLERANCE TO MHC CLASS I-MISMATCHED CARDIAC ALLOGRAFTS IN MINIATURE SWINE
Pezzotta et al. EFFECT OF A NOVEL IMMUNOSUPPRESSANT, ST1959, ON ALLOGENEIC IMMUNE RESPONSE AND RENAL ALLOGRAFT SURVIVAL IN RATS
Mokrý et al. CHARACTERIZATION OF PROPERTIES OF MURINE NEURAL STEM CELLS IN VITRO AND AFTER TRANSPLANTATION
Lloberas et al. DIFFERENT FUNCTIONAL, HISTOLOGICAL AND INMUNOHISTOCHEMICAL PATTERNS INDUCED BY THE ASSOCIATION OF RAPAMYCIN WITH FK506 OR CYCLOSPORINE.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181023

R150 Certificate of patent or registration of utility model

Ref document number: 6429191

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees